{"title":"胰腺癌:一线希望","authors":"S. Nagendram, S. Bhattacharya","doi":"10.1002/tre.904","DOIUrl":null,"url":null,"abstract":"Pancreatic cancer carries a very poor prognosis, with five‐year survival currently approaching 10%. Late presentation, lack of effective treatment options and a tumour microenvironment that subverts immune mechanisms are some of the reasons behind this. Here the authors discuss how advances in our understanding of tumour biology, identification and surveillance of high‐risk groups, improvements in surgical outcomes and the availability of new chemotherapeutic options give us grounds for optimism.","PeriodicalId":42819,"journal":{"name":"Trends in Urology & Mens Health","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pancreatic cancer: a glimmer of hope\",\"authors\":\"S. Nagendram, S. Bhattacharya\",\"doi\":\"10.1002/tre.904\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pancreatic cancer carries a very poor prognosis, with five‐year survival currently approaching 10%. Late presentation, lack of effective treatment options and a tumour microenvironment that subverts immune mechanisms are some of the reasons behind this. Here the authors discuss how advances in our understanding of tumour biology, identification and surveillance of high‐risk groups, improvements in surgical outcomes and the availability of new chemotherapeutic options give us grounds for optimism.\",\"PeriodicalId\":42819,\"journal\":{\"name\":\"Trends in Urology & Mens Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in Urology & Mens Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/tre.904\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Urology & Mens Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/tre.904","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Pancreatic cancer carries a very poor prognosis, with five‐year survival currently approaching 10%. Late presentation, lack of effective treatment options and a tumour microenvironment that subverts immune mechanisms are some of the reasons behind this. Here the authors discuss how advances in our understanding of tumour biology, identification and surveillance of high‐risk groups, improvements in surgical outcomes and the availability of new chemotherapeutic options give us grounds for optimism.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
